Bioxel Pharma, Inc. has won its largest paclitaxel order—valued at about $800,000—from a multinational pharmaceutical company that is currently completing Phase III trials for a paclitaxel-based product. Paclitaxel deliveries under the order will be completed in October 2007, with repeat orders expected in the coming months. Bioxel’s paclitaxel will be incorporated in the client’s NDA, allowing its use in commercial manufacturing and distribution once the product gains marketing...